Bronchoalveolar lavage fluid metagenomic next-generation sequencing assay for identifying pathogens in lung cancer patients

被引:0
作者
Wang, Jiyu [1 ,2 ]
Li, Huixia [1 ,2 ]
Zhou, Deyuan [1 ,2 ]
Bai, Lihong [1 ,2 ]
Tang, Kejing [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Div Pulm & Crit Care Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Inst Pulm Dis, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pharm, Guangzhou, Peoples R China
关键词
Lung cancer; Bronchoalveolar lavage fluid; Metagenomic next-generation sequencing; Infectious diseases; CRITICALLY-ILL PATIENTS; PNEUMONIA; DIAGNOSIS;
D O I
10.32604/biocell.2024.030420
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: For patients with lung cancer, timely identification of new lung lesions as infectious or noninfectious, and accurate identification of pathogens is very important in improving OS of patients. As a new auxiliary examination, metagenomic next -generation sequencing (mNGS) is believed to be more accurate in diagnosing infectious diseases in patients without underlying diseases, compared with conventional microbial tests (CMTs). We designed this study to find out whether mNGS has better performance in distinguishing infectious and non-infectious diseases in lung cancer patients using bronchoalveolar lavage fluid (BALF). Materials and Methods: This study was a real -world retrospective review based on electronic medical records of lung cancer patients with bronchoalveolar lavage (BAL) and BALF commercial mNGS testing as part of clinical care from 1 April 2019 through 30 April 2022 at The First Affiliated Hospital of Sun Yat-sen University. 164 patients were included in this study. Patients were categorized into the pulmonary non-infectious disease (PNID) group (n = 64) and the pulmonary infectious disease (PID) group (n = 100) groups based on final diagnoses. Results: BALF mNGS increased the sensitivity rate by 60% compared to CMTs (81% vs. 21%, p < 0.05), whereas there was no significant difference in specificity (75% vs. 98.4%, p > 0.1). Among the patients with PID, bacteria were the most common cause of infection. Fungal infections occurred in 32% of patients, and Pneumocystis Yersini was most common. Patients with Tyrosine kinase inhibitors (TKIs) therapy possess longer overall survival (OS) than other anti-cancer agents, the difference between TKIs and immunocheckpoint inhibitors (ICIs) was insignificant (median OS TKIs vs. ICIs vs. Anti-angiogenic vs. Chemo vs. Radiotherapy = 76 vs. 84 vs. 61 vs. 58 vs. 60). Conclusions: our study indicates that BALF mNGS can add value by improving overall sensitivity in lung cancer patients with potential pulmonary infection, and was outstanding in identifying Pneumocystis infection. It could be able to help physicians adjust the follow-up treatment to avoid the abuse of antibiotics.
引用
收藏
页码:623 / 637
页数:15
相关论文
共 33 条
[1]   Novel Virus Identification through Metagenomics: A Systematic Review [J].
Bassi, Cristian ;
Guerriero, Paola ;
Pierantoni, Marina ;
Callegari, Elisa ;
Sabbioni, Silvia .
LIFE-BASEL, 2022, 12 (12)
[2]   Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario [J].
Bertaglia, Valentina ;
Morelli, Anna Maria ;
Solinas, Cinzia ;
Aiello, Marco Maria ;
Manunta, Silvia ;
Denaro, Nerina ;
Tampellini, Marco ;
Scartozzi, Mario ;
Novello, Silvia .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 184
[3]   Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors [J].
Bi, Jianping ;
Qian, Jing ;
Yang, Dongqin ;
Sun, Lu ;
Lin, Shouyu ;
Li, Ying ;
Xue, Xudong ;
Nie, Tingting ;
Verma, Vivek ;
Han, Guang .
FRONTIERS IN IMMUNOLOGY, 2022, 12
[4]   Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer [J].
Burns, Ethan A. ;
Gee, Kelly ;
Kieser, Ryan B. ;
Xu, Jiaqiong ;
Zhang, Yuqi ;
Crenshaw, Aubrey ;
Muhsen, Ibrahim N. ;
Mylavarapu, Charisma ;
Esmail, Abdullah ;
Shah, Shivan ;
Umoru, Godsfavour ;
Sun, Kai ;
Guerrero, Carlo ;
Gong, Zimu ;
Heyne, Kirk ;
Singh, Monisha ;
Zhang, Jun ;
Bernicker, Eric H. ;
Abdelrahim, Maen .
CANCERS, 2023, 15 (01)
[5]   A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study [J].
Chihara, Yusuke ;
Takeda, Takayuki ;
Goto, Yasuhiro ;
Nakamura, Yoichi ;
Tsuchiya-Kawano, Yuko ;
Nakao, Akira ;
Onoi, Keisuke ;
Hibino, Makoto ;
Fukuda, Minoru ;
Honda, Ryoichi ;
Yamada, Takahiro ;
Taniguchi, Ryusuke ;
Sakamoto, Sinjiro ;
Date, Koji ;
Nagashima, Seiji ;
Tanzawa, Shigeru ;
Minato, Koichi ;
Nakatani, Koichi ;
Izumi, Miiru ;
Shimose, Takayuki ;
Kishimoto, Junji ;
Uchino, Junji ;
Takayama, Koichi .
ONCOLOGIST, 2022, 27 (11) :903-E834
[6]   Diagnosis and Treatment to a Post-Craniotomy Intracranial Infection Caused by Corynebacterium [J].
Fan, Caixia ;
Gong, Li ;
An, Mo ;
Li, Zhenglin ;
Li, Xiang ;
Fang, Jinzhi .
INFECTION AND DRUG RESISTANCE, 2022, 15 :6681-6687
[7]   T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy [J].
Gao, Zhanyan ;
Feng, Yang ;
Xu, Jinhua ;
Liang, Jun .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[8]   Metagenomics Next Generation Sequencing (mNGS): An Exciting Tool for Early and Accurate Diagnostic of Fungal Pathogens in Plants [J].
Gokdemir, Fatma Seyma ;
Iseri, Ozlem Darcansoy ;
Sharma, Abhishek ;
Achar, Premila N. ;
Eyidogan, Fusun .
JOURNAL OF FUNGI, 2022, 8 (11)
[9]   Antimicrobial Proteins: Structure, Molecular Action, and Therapeutic Potential [J].
Hassan, Mohamed ;
Flanagan, Thomas W. ;
Kharouf, Naji ;
Bertsch, Christelle ;
Mancino, Davide ;
Haikel, Youssef .
PHARMACEUTICS, 2023, 15 (01)
[10]   Clinical Characteristics and the Effect of Timing for Metagenomic Next-Generation Sequencing in Critically Ill Patients with Sepsis [J].
He, Dehua ;
Liu, Ming ;
Chen, Qimin ;
Liu, Ying ;
Tang, Yan ;
Shen, Feng ;
Wang, Difen ;
Liu, Xu .
INFECTION AND DRUG RESISTANCE, 2022, 15 :7377-7387